# Morgan Stanley (MS) fundamentals

Data as of 2026-09-08. NYSE, United States. Sector: Financial Services / Capital Markets. Price $217.72, market value $341.9 billion.

## Valuation
- **P/E (trailing): 17.6×** (5-yr avg 14.4×, 3-yr avg 16.4×). Morgan Stanley trades at 17.6× trailing earnings, well above its own five-year average of 14.4×: investors are paying up relative to the company's past. The Financial Services median in the September 2026 study was 13.1×. Forward P/E is 16.0×, lower than trailing, so analysts expect earnings to grow.
- **PEG: 0.56**. A PEG of 0.56 means the P/E is low relative to expected earnings growth: the market is not paying much for that growth.
- **Price / sales: 4.4×**. Each dollar of revenue is priced at 4.4×.
- **Price / book: 3.2×**. The shares trade at 3.2× book value; book value is a meaningful part of the valuation.
- **Earnings yield: 5.7%**. The inverse of the P/E: 5.7% of the price is earned each year.

## Profitability
- **Net margin: 23.9%**. 23.9% of each dollar of sales reaches the bottom line.
- **Return on equity: 15.1%**. 15.1% on shareholders' equity is solid.
- **Return on assets: 1.4%**. Each dollar of assets produces 1.4% of profit; low single digits are normal for banks and insurers.

## Growth
- **Revenue growth (1 yr): 14.4%** (3-yr 9.6%/yr, 5-yr 7.7%/yr). Revenue grew 14.4% over the last year, against 7.7% a year compounded over five years: growth is accelerating.
- **EPS growth (1 yr): 28.4%** (3-yr 18.4%/yr, 5-yr 9.6%/yr). Earnings per share rose 28.4%, faster than revenue, so margins expanded or the share count shrank.

## Financial health
- **Piotroski F-score: 3/9**. 3 of 9 checks pass: weak or deteriorating financials.
- **Cash and short-term investments: $111.7 billion**. Leverage ratios are shown differently for banks and insurers, whose balance sheets are built on deposits and reserves; use return on equity and the regulatory capital in the filings instead.

## Dividends
- **Dividend yield: 2.11%** ($4.15 per share, trailing). Morgan Stanley yields 2.11%, a modest yield more typical of a growth-oriented payer.
- **Payout ratio: 39%**. 39% of earnings goes out as dividends, leaving room to keep raising it.
- **Consecutive years of increases: 15**. 15 straight years of increases, a record that survived at least one recession.
- **Dividend growth (5 yr): 22.4%/yr** (1-yr 8.5%). The dividend has compounded at 22.4% a year over five years, doubling roughly every 3 years at that pace.

## Analyst view
- **Analyst consensus: buy** (21 analysts). 21 analysts cover Morgan Stanley; the consensus is buy, with an average price target of $236.62 (+9% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): 47.1%** (YTD 24.0%, 3-mo 2.7%). The shares are up 47.1% over twelve months including dividends.
- **From 52-week high: -6.3%** (46.8% above the low). Trading 6% below its 52-week high.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 55**. An RSI of 55 is neutral.
- **Beta (1 yr): 1.38** (volatility 28%). Beta of 1.38 against the S&P 500: the shares move much more than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=MS · Page: https://foliofundamentals.com/stocks/ms

Not investment advice.